Published in Psychosom Med on May 30, 2001
The connection between art, healing, and public health: a review of current literature. Am J Public Health (2009) 2.54
Determinants of surgery related anxiety in cataract patients. Br J Ophthalmol (2004) 1.20
Music and social bonding: "self-other" merging and neurohormonal mechanisms. Front Psychol (2014) 1.17
The effect of music on the human stress response. PLoS One (2013) 0.93
A Tool for Music Preference Assessment in Critically Ill Patients Receiving Mechanical Ventilatory Support. Music Ther Perspect (2009) 0.90
Previous exposure to musical auditory stimulation immediately influences the cardiac autonomic responses to the postural change maneuver in women. Int Arch Med (2013) 0.82
Instituting a music listening intervention for critically ill patients receiving mechanical ventilation: Exemplars from two patient cases. Music Med (2011) 0.78
Singing intervention for preoperative hypertension prior to total joint replacement: a case report. Arthritis Care Res (Hoboken) (2011) 0.75
Blood Pressure and Heart Rate Alterations through Music in Patients Undergoing Cataract Surgery in Greece. Ophthalmol Eye Dis (2015) 0.75
Music and medicine. J Multidiscip Healthc (2010) 0.75
Listening to music during ambulatory ophthalmic surgery reduced blood pressure, heart rate, and perceived stress. Evid Based Nurs (2002) 0.75
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother (2011) 4.21
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother (1998) 2.19
Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother (1984) 1.98
Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.97
Captopril reduces urinary cystine excretion in cystinuria. Arch Intern Med (1987) 1.61
Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci (1981) 1.55
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother (1985) 1.46
Degradation of 131 I-insulins by rat liver. Studies in vitro. J Biol Chem (1972) 1.43
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis (2000) 1.32
Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene (2001) 1.29
Pet ownership, but not ace inhibitor therapy, blunts home blood pressure responses to mental stress. Hypertension (2001) 1.26
Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.23
Physiological processes and dynamics in the disposition of small and large doses of biologically active and inactive 131-I-insulins in the rat. J Biol Chem (1967) 1.23
Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1987) 1.22
Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother (2006) 1.22
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother (1986) 1.18
An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther (1988) 1.18
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother (1987) 1.17
The estimation of Widmark's factor. J Forensic Sci Soc (1986) 1.14
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm (2000) 1.12
The link between pharmacodynamics and physiologically based pharmacokinetic models. Clin Pharmacol Ther (2013) 1.12
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother (1987) 1.12
Regulation of CDC25B phosphatases subcellular localization. Oncogene (2000) 1.09
Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother (1993) 1.08
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Eur J Clin Microbiol (1984) 1.08
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res (1985) 1.07
Propranolol dosage in thyrotoxicosis. J Clin Endocrinol Metab (1980) 1.06
Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation. J Clin Pharm Ther (2002) 1.06
Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother (1994) 1.05
Vascular reactivity in patients with peripheral vascular disease. Am J Cardiol (1995) 1.04
A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Ther (1989) 1.02
The simulation of psychosis: a contemporary presentation. Br J Med Psychol (1970) 1.02
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res (1987) 1.01
Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. J Pharm Sci (1981) 1.00
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother (1989) 1.00
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther (2009) 1.00
Ca2+-induced Ca2+ release involved in positive inotropic effect mediated by CGRP in ventricular myocytes. Am J Physiol (1999) 0.98
Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther (1999) 0.97
Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers. Clin Drug Investig (1998) 0.97
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob Agents Chemother (2013) 0.97
Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol (1998) 0.97
Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol (2003) 0.96
Seasonal variation in haemodynamics and blood pressure-regulating hormones. J Hum Hypertens (2009) 0.95
The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition. J Clin Invest (1978) 0.95
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia (2009) 0.95
Active miniature transposons from a plant genome and its nonrecombining Y chromosome. Genetics (2008) 0.95
Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. Am J Cardiol (1987) 0.95
Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. J Clin Pharmacol (1997) 0.95
Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther (1989) 0.94
Hyperventilation-induced T-wave changes in the limb lead electrocardiogram. Chest (1975) 0.92
Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther (1997) 0.92
Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis (1998) 0.90
Controlled trial of depot fluphenazine in out-patient schizophrenics. Br J Psychiatry (1974) 0.90
Concentration- or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther (1994) 0.90
Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother (1999) 0.89
Effect of saturable clearance during high-dose mezlocillin therapy. Antimicrob Agents Chemother (1984) 0.89
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res (1989) 0.89
Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation. J Clin Pharmacol (1994) 0.89
Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother (1986) 0.88
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. HIV Med (2013) 0.88
AMGET, an R-Based Postprocessing Tool for ADAPT 5. CPT Pharmacometrics Syst Pharmacol (2013) 0.88
Tumor volume and treatment outcome in small cell lung carcinoma. Invest Radiol (1989) 0.88
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther (2001) 0.88
Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother (1995) 0.87
AUIC--the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother (1996) 0.87
Geographical variation in the Atlantic salmon. Nature (1971) 0.87
Factors associated with postoperative infection. Infect Control Hosp Epidemiol (2001) 0.86
Human urinary and plasma kinins: relationship to sodium-retaining steroids and plasma renin activity. Circ Res (1979) 0.86
Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers. Antimicrob Agents Chemother (1987) 0.86
Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension (1995) 0.85
Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol (2000) 0.85
Subcellular distribution of intraportally injected 125I-labeled insulin in rat liver. Arch Biochem Biophys (1979) 0.84
Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans. Antimicrob Agents Chemother (2000) 0.84
Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension (1999) 0.83
Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Antimicrob Agents Chemother (1997) 0.83
Influence of renal perfusion pressure on alpha- and beta-adrenergic stimulation of renin release. Am J Physiol (1985) 0.83
Plasma dihydroxyphenylglycol (DHPG) in the in vivo assessment of human neuronal norepinephrine metabolism. Life Sci (1985) 0.83
Treatment of hypertension in a managed care setting. Am J Manag Care (2001) 0.83
A preliminary trial of the gel test for blood group serology. Br J Biomed Sci (1993) 0.82
A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res (1989) 0.82
Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. Antimicrob Agents Chemother (1985) 0.82
Acid-suppressive therapy use associated with antihypertensive agents. J Clin Pharmacol (2001) 0.82
Age and prior caffeine use alter the cardiovascular and adrenomedullary responses to oral caffeine. Am J Cardiol (1983) 0.82
Physiologic mechanisms opposing the hemodynamic effects of prazosin. Clin Pharmacol Ther (1981) 0.81
Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens (1997) 0.81
Insulin-glucose dispersion and interaction system. Liver control mechanisms. Arch Intern Med (1969) 0.81
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol (1991) 0.81
Digoxin concentrations in serum and saliva. Res Commun Chem Pathol Pharmacol (1975) 0.81
Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers. J Clin Pharmacol (1998) 0.81
Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): a placebo-controlled evaluation. J Int Med Res (2002) 0.81
Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients. Pharmacoeconomics (2000) 0.81
The sympathoadrenal system in the maintenance of elevated arterial pressure. J Cardiovasc Pharmacol (1984) 0.81
Transluminal recanalization of an occluded renal artery: reversal of anuria in a patient with a solitary kidney. AJR Am J Roentgenol (1981) 0.80
Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. Ann Pharmacother (1997) 0.80
Hemodynamic response to volume depletion in acutely uremic dogs. Am J Physiol (1984) 0.80
Use of adaptive control with feedback to individualize suramin dosing. Cancer Res (1992) 0.80
Weight-based heparin dosing: clinical response and resource utilization. Clin Ther (1998) 0.80